Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication protects patients with peanut allergies

11.03.2003


Study shows life-threatening reactions from accidental ingestion can be avoided



A new medication could help most people with peanut allergies avoid life-threatening allergic reactions, according to a report in the March 14 issue of the New England Journal of Medicine. A research team led by Donald Leung, M.D., Ph.D. of National Jewish Medical and Research Center, and Hugh Sampson, M.D. of Mount Sinai School of Medicine, found that treatment with an anti-IgE antibody raised the average level at which study participants began reacting to peanuts from about half a peanut to almost nine peanuts. Researchers estimate that most of the 50-100 annual fatal reactions to peanuts occur after an allergic person accidentally eats the equivalent of just one to two nuts. The researchers also presented their findings March 10 in Denver at the annual meeting of the American Academy of Allergy, Asthma & Immunology IgE is the molecule that binds to a group of cells called mast cells, which then trigger the allergic response. Food allergy symptoms can range from nausea and itching to anaphylactic shock and death. TNX-901, the treatment used in this study, is a genetically engineered antibody made by Tanox Inc. that binds to the IgE molecule and prevents it from triggering the allergic response.

"Our results indicate that the anti-IgE antibody could become the first preventive medicine for peanut allergies," said Dr. Leung. "If future studies bear out this initial promise, anti-IgE could not only save lives, but help lift a cloud of fear that people with peanut allergies live under every time they eat."


Approximately 1.5 million people in the U.S. have peanut allergy, the leading cause of severe allergic reactions. Each year, thousands of people rush to hospital emergency rooms, and approximately 50 to 100 people die after accidentally eating peanuts. Strict avoidance is the only means of preventing an allergic reaction. But, that can be difficult to impossible, especially, since food labels do not always mention tiny amounts of peanuts that are found in some foods. An earlier study found that fatal reactions can occur after such difficult to avoid situations as eating a tuna sandwich made with a knife that had not been thoroughly cleaned after spreading peanut butter or eating cookies that were made on factory equipment that had earlier been used to make other cookies with peanuts. Existing medications, including epinephrine, antihistamines, bronchodilators, and charcoal pills, are taken only after the peanuts have been eaten and are not always effective.

"Anti-IgE therapy is not a cure for peanut allergy," said Dr. Sampson. "We believe that patients would have to continue the injections for the benefits to persist and they still would need to be careful about what they eat. But, because the amount they could consume without serious reaction would be greatly increased, the fear of accidental ingestion that detracts from quality of life for many patients would be eliminated. These are very promising results."

Blocking IgE is considered a major advance because it inhibits the allergic response at an earlier stage than other medicines, effectively stopping it before it begins. A slightly different anti-IgE molecule has shown promise in treating severe hay fever and asthma. In the current randomized, double-blinded, placebo-controlled study, 82 people ages 12 to 60 with severe peanut allergy were given four injections at monthly intervals of either a placebo or one of three doses (150 mg, 300 mg , or 450mg) of TNX-901. Before the trial began, each patient underwent an oral food challenge with increasing doses of peanut flour and a food challenge with a placebo to establish their sensitivity to peanuts. Patients were monitored closely during the challenges. Each challenge was halted and treatment begun as soon as a doctor determined that an allergic reaction had begun. Symptoms that commonly signaled an allergic reaction included nausea, abdominal pain, vomiting, throat or chest tightness, wheezing, itching, cough, and hives. Each patient’s threshold sensitivity to peanuts was considered the amount of peanut flour consumed immediately before the challenge was stopped. TNX-901 was well tolerated with no significant side effects.

Blood levels of IgE were measured before the injections began and periodically throughout the test. Two to four weeks after the final injection, patients underwent one more food challenge with peanut flour.

TNX-901 raised patients’ threshold sensitivity to peanut flour in a dose-responsive manner. The threshold sensitivity for patients receiving the largest dose (450 mg) of TNX-901 increased from an average of 177 mg to 2,805 mg. The average accidental ingestion is estimated to one to two peanuts or about 325 mg to 650 mg. Nearly a quarter of the patients receiving the highest dose of TNX-901 consumed 8,000 mg, or about 24 peanuts, with no reaction. Many patients still reacted to peanuts even after the injections. But on average, they could eat more peanuts without a reaction, and reacted less vigorously to the peanuts they did eat.


###
Other medical centers participating in the trial included Mayo Clinic in Rochester, MN; Arkansas Children’s Hospital in Little Rock, AK; and Children’s Hospital in Boston, MA.

William Allstetter | EurekAlert!
Further information:
http://www.njc.org/

More articles from Health and Medicine:

nachricht 'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers
16.02.2018 | National University of Science and Technology MISIS

nachricht New process allows tailor-made malaria research
16.02.2018 | Eberhard Karls Universität Tübingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

Im Focus: Autonomous 3D scanner supports individual manufacturing processes

Let’s say the armrest is broken in your vintage car. As things stand, you would need a lot of luck and persistence to find the right spare part. But in the world of Industrie 4.0 and production with batch sizes of one, you can simply scan the armrest and print it out. This is made possible by the first ever 3D scanner capable of working autonomously and in real time. The autonomous scanning system will be on display at the Hannover Messe Preview on February 6 and at the Hannover Messe proper from April 23 to 27, 2018 (Hall 6, Booth A30).

Part of the charm of vintage cars is that they stopped making them long ago, so it is special when you do see one out on the roads. If something breaks or...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Fingerprints of quantum entanglement

16.02.2018 | Information Technology

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers

16.02.2018 | Health and Medicine

Hubble sees Neptune's mysterious shrinking storm

16.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>